PubRank
Search
About
Tito Mendoza
Author PubWeight™ 13.79
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Epidural and intrathecal analgesia is effective in treating refractory cancer pain.
Pain Med
2004
1.49
2
A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients.
Cancer J
2014
1.40
3
Validation of the German version of the brief fatigue inventory.
J Pain Symptom Manage
2003
1.05
4
Vertebral compression fracture treatment with vertebroplasty and kyphoplasty: experience in 407 patients with 1,156 fractures in a tertiary cancer center.
Pain Med
2011
1.00
5
Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients.
Oncology
2004
1.00
6
Psychometric testing of the MDASI-HF: a symptom assessment instrument for patients with cancer and concurrent heart failure.
J Card Fail
2008
0.98
7
Argon beam coagulation as an adjuvant for local control of giant cell tumor.
Clin Orthop Relat Res
2007
0.98
8
Health care providers' assessments of the quality of advanced-cancer care in Latin American medical institutions: a comparison of predictors in five countries: Argentina, Brazil, Cuba, Mexico, and Peru.
J Pain Palliat Care Pharmacother
2008
0.94
9
The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients.
Cancer
2011
0.92
10
Pain in thalassaemia: the effects of age on pain frequency and severity.
Br J Haematol
2012
0.91
11
Congruence of primary brain tumor patient and caregiver symptom report.
Cancer
2012
0.88
12
The analgesic effects that underlie patient satisfaction with treatment.
Pain
2004
0.81
13
Pediatric cancer pain management practices and attitudes in China.
J Pain Symptom Manage
2003
0.79
14
Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.
Expert Rev Pharmacoecon Outcomes Res
2011
0.76